# Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL 

Source: https://onco.cc/trials/nct06463665/  
OnCo record `nct06463665` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Olvimulogene nanivacirepvec, Nivolumab, Cemiplimab in non-small-cell lung cancer and small-cell lung cancer, run by Genelux Corporation, now recruiting.

## Summary

Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer is a phase 2 interventional study registered as NCT06463665 by Genelux Corporation, with 142 participants planned, started 2024-09-26 and due to reach its primary completion in 2027-02. Interventions recorded: Olvimulogene nanivacirepvec, Platinum chemotherapy: carboplatin or cisplatin, Non-platinum chemotherapy: paclitaxel or nab-paclitaxel for squamous cell NSCLC or pemetrexed for nonsquamous cell NSCLC, Physician's Choice of Immune Checkpoint Inhibitor: pembrolizumab, nivolumab, cemiplimab, atezolizumab, durvalumab, Docetaxel. Conditions listed: Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Squamous Non-Small Cell Lung Carcinoma, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Squamous Non-Small Cell Lung Carcinoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06463665
- Phase: 2
- Setting: A Randomized Phase 2 Study Assessing the Efficacy and Safety of Olvimulogene Nanivacirepvec Followed by Platinum-doublet Chemotherapy + Physician's Choice of Immune Checkpoint Inhibitor Compared With Docetaxel in Patients With NSCL Cancer After First Progression While on Front-line Immune Checkpoint Inhibitor-based Maintenance
- Sponsor: Genelux Corporation
- Enrolled: 142

## Sources

- ClinicalTrials.gov NCT06463665: https://clinicaltrials.gov/study/NCT06463665

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Atezolizumab](https://onco.cc/drugs/atezolizumab/), [Cemiplimab](https://onco.cc/drugs/cemiplimab/), [Docetaxel](https://onco.cc/drugs/docetaxel/), [Durvalumab](https://onco.cc/drugs/durvalumab/), [Nivolumab](https://onco.cc/drugs/nivolumab/), [Olvimulogene nanivacirepvec](https://onco.cc/drugs/olvimulogene-nanivacirepvec/)
- companies: [Genelux](https://onco.cc/companies/genelux/)

---
JSON: https://onco.cc/api/v1/entities/nct06463665.json